Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04209855
Title A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors ImmunoGen, Inc.

ovarian serous carcinoma

fallopian tube cancer

peritoneum cancer



Pegylated liposomal-doxorubicin

Mirvetuximab Soravtansine


Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.